Targeting serious diseases of
immuno-inflammation and fibrosis
Our lead product candidate cenicriviroc (CVC) is under evaluation to treat non-alcoholic steatohepatitis (NASH) with liver fibrosis and other serious illnesses
NASH is a severe type of non-alcoholic fatty liver disease, or NAFLD. NASH affects 3 to 5 percent of the US population and can lead to life-threatening complications such as cirrhosis and liver cancer. There are no approved therapies for patients suffering from this severe condition.
Tobira is evaluating CVC’s efficacy and safety in multiple clinical studies, including the CENTAUR Study, an international, randomized Phase 2b study of CVC vs placebo in patients with NASH and liver fibrosis (NCT02217475).
CVC Development in NASH
CVC Development in Immuno-Inflammatory Diseases
- 4.8.15 Tobira Therapeutics Highlights Presentations at The International Liver Congress 2015
- 3.20.15 Tobira Therapeutics Highlights Presentations at the AASLD’s Industry Colloquium for Novel Targets and Therapies in Liver Disease
- 3.9.15 Tobira Therapeutics Closes Financing to Support Development of CVC in Non-Alcoholic Steatohepatitis